Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | CA7 | P43166 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 3/20 | 0.46 |
| ▸ | CTSL | P07711 | 2/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | REN | P00797 | 2/20 | 0.41 |
| ▸ | BACE1 | P56817 | 2/20 | 0.41 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5170605 | 1.00 | CA1 (0.55) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL6487911 | 1.00 | CA1 (0.55) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL7167201 | 0.87 | CA1 (0.53) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL7167204 | 0.87 | CA1 (0.53) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL7364723 | 0.86 | CA1 (0.57) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL12018725 | 0.86 | CA1 (0.57) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL10982144 | 0.86 | CA1 (0.57) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL10727796 | 0.84 | CA1 (0.55) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL10573143 | 0.83 | CA1 (0.62) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL15614935 | 0.83 | CA1 (0.62) | CA1CA2CA7CYP2D6CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6888012-B2 | Reducing an alpha -haloketone compound by asymmetric hydrogen transfer in presence of a group 9 transition metal compound having a substituted or unsubstituted cyclopentadienyl group and an optically active diamine compound | AJINOMOTO CO., INC. (JP) | 2005-05-03 | — | — | US | disclosed |
| US-20040082820-A1 | Hydrogen transfer reduction; useful as intermediate for production of pharmaceuticals/agricultural chemicals | AJINOMOTO CO., INC. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1346972-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE HALOHYDRIN COMPOUND | Ajinomoto Co., Inc. (JP) | 2003-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082820-A1 | Hydrogen transfer reduction; useful as intermediate for production of pharmaceuticals/agricultural chemicals | DHPS, HDHD5, HYPK | CA1 1783/4885CA2 1118/4885CA7 731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.